▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

Mursla Bio Introduces AI Precision Medicine Platform Built on Organ-Specific EV Isolation from Blood

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve cancer outcomes for at-risk patients, today announced the commercial ...

Business Wire
  • Platform is built on biologically labelled, organ-specific multi-omics data carried by extracellular vesicles isolated from 2ml plasma samples
  • Enables differentiated AI-powered biomarker discovery and IVD translation for patient stratification, therapeutic monitoring, surrogate markers and other diagnostic development programs
  • Publication of pre-print data, with support from Evotec International GmbH and University College London demonstrates validation of Platform’s capability for liver diseases

CAMBRIDGE, England & BOSTON: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve cancer outcomes for at-risk patients, today announced the commercial launch of its AI Precision Medicine Platform, alongside a pre-print¹ reporting the first validated method for isolating hepatocyte EVs from plasma for organ-specific proteomic and miRNA profiling. Mursla Bio is engaging with potential partners to apply its Platform to additional disease areas, biomarker discovery and IVD translation programs.

The Platform addresses a major gap in liquid biopsy and precision medicine: enabling non-invasive access to organ-specific molecular information from blood with high spatial and biological resolution. Mursla Bio’s Platform is built on its ability to isolate and analyze EVs which are secreted by specific organs into the bloodstream. The Platform reduces non-target background by up to five orders of magnitude compared to standard bulk EV isolation and significantly improves data structure, enhancing prediction model generalization.

The pre-print presents the first multi-layered validation of hepatocyte EV isolation in humans, confirming liver origin through proteomic and nucleic acid markers. Key supporting proteomics data was generated in collaboration with Evotec International GmbH. Patient samples were provided by University College London, with Professor Brian Davidson, a global leader in liver disease surgery and clinical research, contributing as a co-author. The study shows that Mursla Bio’s method yields robust, organ-specific multi-omics data using minimal blood volume, offering a novel scalable approach for biomarker and AI development.

Mursla Bio’s Platform incorporates optimized multi-omics workflows, embedded AI pipelines, and IVD translation processes to convert complex biological signals into practical, regulatory-grade assays. These assays are deployable on standard commercial instruments using patented, PCR and ELISA-like steps designed for clinical adoption. The Platform also underpins the development of EvoLiver™, the Company’s lead clinical program for liver cancer surveillance in cirrhotic patients. Built on multi-omics data from over 300 patients, EvoLiver achieved 86% sensitivity and 88% specificity on a locked, IVD-compatible assay for early-stage hepatocellular carcinoma detection², and has received Breakthrough Device Designation from the FDA³.

Pierre Arsène, Founder and CEO of Mursla Bio, said: "EVs are nature’s native signal enrichment system for long-distance communication between cells and organs. Our platform harnesses this biology to non-invasively access organ-specific, multi-omics data from just a small blood sample. It produces structured, biologically labeled datasets that are optimized for AI and ready to support diagnostic translation. EvoLiver is our first proof point of real-world clinical impact, and we are now expanding access to the platform to advance our pipeline and enable partnerships across other disease areas.”

Mursla Bio is expanding its pipeline and collaborations, with additional organ programs underway in cardiometabolic, lung, and neurological indications. The Platform will support pharma development through dynamic patient stratification, therapeutic response monitoring, surrogate markers and molecular phenotyping across complex disease biology.

For further information on Mursla Bio’s AI Precision Medicine Platform, please visit https://mursla.com/ai-precision-platform/.

  • Organ-specific isolation of hepatocyte extracellular vesicles from human plasma enables tissue-resolved proteomic and miRNA profiling”
  • Mursla Bio’s EvoLiver surpasses current standards in liver cancer surveillance
  • Mursla Bio receives FDA Breakthrough Device Designation for EvoLiver™ test
  •  

    Fonte: Business Wire

    If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

    Related news

    Last News

    RSA at Cybertech Europe 2024

    Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

    Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

    G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

    How Austria is making its AI ecosystem grow

    Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

    Sparkle and Telsy test Quantum Key Distribution in practice

    Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

    Most read

    AI Strengthening Cybersecurity Software, ISG Says

    $III #AI--Growing and evolving security threats make it increasingly important for enterprises to deploy advanced cybersecurity software and to understand…

    Mitsubishi Electric’s ME Innovation Fund Invests in AI-assisted PLM Systems…

    Mitsubishi Electric Corporation (TOKYO: 6503) announced today that its ME Innovation Fund has invested in Things, Inc., a Japan-based startup that develops…

    Team8 Expands Cyber and AI Focus with New Partner Appointments, Ori Barzilay…

    Team8 a global venture fund that builds and invests in companies across cybersecurity, data, AI, fintech, and digital health, as well as their intersections…

    PropStream Announces Acquisition of Batch Leads and Batch Dialer, Enhancing…

    #BrianTepfer--PropStream, a leading real estate data and analytics platform and company in the Stewart Information Services Corporation family of companies…

    Newsletter signup

    Join our mailing list to get weekly updates delivered to your inbox.

    Sign me up!